2017 NCCN Case Manager and Medical Director Program: Updates in the Diagnosis and Treatment of Lung Cancer
Join Gregory A. Otterson, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute as he presents Updates in the Diagnosis and Treatment of Lung Cancer as part of the NCCN 2017 Oncology Case Manager and Medical Director Program Webinar Series.
Many therapeutic options exist for patients with non-small cell lung cancer (NSCLC), but the different options can seem overwhelming for patients who need educating about the options before making decisions. The NCCN Guidelines for Patients® are a valuable resource for educating patients about lung cancer. Case managers and other healthcare professionals involved in care planning and coordination need to be knowledgeable about all the treatment options and biomarker testing recommendations for patients with NSCLC and need to be aware that recommendations are rapidly changing so they can discuss the risks, benefits, and appropriateness with each patient. Healthcare professionals also need to be aware of new NCCN tools for quickly and accurately educating patients about the different therapeutic options based on efficacy, safety, quality and consistency of the evidence, and affordability (see the NCCN Clinical Practice Guidelines in Oncology® with NCCN Evidence Blocks™ for Non-Small Cell Lung Cancer). Informed shared decision making can enable patients to receive high-quality and cost-effective care that maximizes their survival while taking into account their values and preferences.
This program is designed to meet the educational needs of case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.
Following this activity, participants should be able to:
- Educate patients by providing a broad overview of lung cancer.
- Discuss appropriate biomarker tests for patients with non-small cell lung cancer (NSCLC).
- Describe the different types of immunotherapy and targeted therapy for patients with metastatic NSCLC.
Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hour of Category I credits for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.25 contact hours.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. If approved, Activity Code and Approval Number will be posted prior to activity date.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. Universal Activity Number (UAN) will be posted prior to activity date.
- 1.25 CCM clock hours
- 1.25 ACPE contact hours
- 1.25 ANCC contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Participation
Click the Take Course button to register for this live webinar.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing